RongaG, FilesiM, MontesanoT, Di NicolaAD, PaceC, TravascioL, VentroniG, AntonaciA, VestriAR. 2004. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging, 48:12–19.
2.
BrownRL. 2008. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol, 35:298–308.
3.
SchlumbergerMJ. 1999. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest, 22:3–7.
4.
RobbinsRJ, SchlumbergerMJ. 2005. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med, 46:28S–37S.
5.
TuttleRM, LeboeufR, RobbinsRJ, QualeyR, PentlowK, LarsonSM, ChanCY. 2006. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med, 47:1587–1591.
6.
RallJE, AlpersJB, LewallenCG, SonenbergM, BermanM, RawsonRW. 1957. Radiation pneumonitis and fibrosis: a complication of radioiodine treatment of pulmonary metastases from cancer of the thyroid. J Clin Endocrinol Metab, 17:1263–1276.
7.
ZhuRS, YuYL, LuHK, LuoQY, ChenLB. 2005. Clinical study of 312 cases with metastatic differentiated thyroid cancer treated with large doses of 131I. Chin Med J (Engl), 118:425–428.
8.
SchlumbergerM, ChalletonC, De VathaireF, TravagliJP, GardetP, LumbrosoJD, FranceseC, FontaineF, RicardM, ParmentierC. 1996. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med, 37:598–605.
9.
IlganS, KaracaliogluAO, PabuscuY, AtacGK, ArslanN, OzturkE, GunalpB, OzguvenMA. 2004. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging, 31:825–830.
10.
LusterM, LassmannM, FreudenbergLS, ReinersC. 2007. Thyroid cancer in childhood: management strategy, including dosimetry and long-term results. Hormones (Athens), 6:269–278.
11.
ReinersC, DemidchikYE, DrozdVM, BikoJ. 2008. Thyroid cancer in infants and adolescents after Chernobyl. Minerva Endocrinol, 33:381–395.
12.
DornR, KoppJ, VogtH, HeidenreichP, CarrolRG, GulecSA. 2003. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med, 44:451–456.
13.
SongH, HeB, PrideauxA, DuY, FreyE, KasecampW, LadensonPW, WahlRL, SgourosG. 2006. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med, 47:1985–1994.
14.
BenuaRS, LeeperRD. 1986. A method, rationale for treating metastatic thyroid carcinoma with the largest safe dose of 131I. Medeiros-NetaG, GaitanE. Frontiers in Thyroidology. Plenum Medical: New York, 1317–1321.
15.
HughesJM, LockwoodDN, JonesHA, ClarkRJ. 1991. DLCO/Q and diffusion limitation at rest and on exercise in patients with interstitial fibrosis. Respir Physiol, 83:155–166.
16.
HsiehSH, HuangMJ, KaoPF, HuangBY, HuangHS. 1992. Low dose radioiodine treatment of papillary thyroid carcinoma in a child—a case report. Changgeng Yi Xue Za Zhi, 15:220–225.
17.
CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, ShermanSI, TuttleRM. 2006. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16:109–142.
